CTOs on the Move

DPT Laboratories

www.dptlabs.com

 
DPT is a contract development and manufacturing organization specializing in semi-solid and liquid dosage forms. Recognized globally for technical expertise and virtually unlimited manufacturing capabilities, DPT is the industry source for fully
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.dptlabs.com
  • 307 E Josephine St
    San Antonio, TX USA 78215
  • Phone: 210.476.8100

Executives

Name Title Contact Details

Similar Companies

Hi-Tech Pharmacal Co Inc

Hi-Tech Pharmacal Co Inc is a Amityville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metrics

Metrics provides pharmaceutical product development including pre-formulation studies, formulation development, clinical trial batch manufacturing and clinical trial batch packaging and labeling for non-sterile dosage forms. In addition, Metrics

FSD Pharma

FSD Pharma is transforming a large facility in Cobourg, Ontario Canada, into the largest hydroponic indoor cannabis production and processing facility in the world, with multiple business units co-supporting each other, operating under a single roof to exploit economies of scale and operational efficiencies. We are growing the future through innovation!

Qualitest Pharmaceuticals

Qualitest Pharmaceuticals is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Acer Therapeutics

Acer Therapeutics is a biotech company, headquartered in Cambridge, MA, that develops repurposed and reformulated medicines for the treatment of ultra-orphan diseases with significant unmet medical needs. Acer`s lead candidate, EDVISO™ (celiprolol), is the first pharmaceutical therapy seeking approval for patients with vascular-type Ehlers-Danlos syndrome (vEDS). Ehlers-Danlos Syndrome is a group of hereditary disorders of connective tissue with no ethnic predisposition. vEDS is a subtype characterized by severe arterial dissections, ruptures and early death. Complications are rare in childhood, but affect 25% of patients before the age of 20, and 80% by the age of 40. Median age of death is estimated to be around 50 years. Patients are diagnosed by clinical symptoms and confirmed by presence of mutations in the COL3A1 gene. There are approximately 2,000 documented patients, but prevalence could be as high as 5,000 patients in the U.S. (Pepin 2014). There are no specific pharmacological treatments for vEDS and medical intervention centers on symptomatic treatment, prophylactic measures and genetic counseling. Acer was awarded orphan drug designation by the FDA in January 2015. Acer`s second candidate, ACER-001, is the first pharmaceutical therapy being developed for patients with Maple Syrup Urine Disease (MSUD). MSUD is a devastating genetic disease – an inborn error of amino acid metabolism. Approximately 800 patients suffer from MSUD in the U.S. and 3,000 worldwide. There are no therapeutic options for MSUD and diet is not enough. Despite careful dietary management, the majority of MSUD patients have chronic neurological and social impairment, as well as life-threatening episodes of intoxication. Acer was awarded orphan drug designation by the FDA in August 2014.